Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.61 USD | +3.54% | +20.22% | +67.25% |
Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Mar. 14 | Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 486M |
---|---|---|---|---|---|
Net income 2024 * | -79M | Net income 2025 * | -144M | EV / Sales 2024 * | - |
Net cash position 2024 * | 182M | Net cash position 2025 * | 57.6M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.17
x | P/E ratio 2025 * |
-3.63
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.66% |
Latest transcript on Larimar Therapeutics, Inc.
1 day | +3.54% | ||
1 week | +20.22% | ||
Current month | +10.45% | ||
1 month | +3.40% | ||
3 months | +23.74% | ||
6 months | +164.24% | ||
Current year | +67.25% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 65 | - | |
Michael Celano
DFI | Director of Finance/CFO | 65 | 20-05-27 |
Noreen Scherer
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20-05-27 |
Frank Thomas
BRD | Director/Board Member | 54 | 20-05-27 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 23-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.04% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 7.61 | +3.54% | 220,416 |
24-05-01 | 7.35 | +6.68% | 388,503 |
24-04-30 | 6.89 | +4.24% | 266,235 |
24-04-29 | 6.61 | +2.64% | 296,313 |
24-04-26 | 6.44 | +1.74% | 144,231 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.25% | 469M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- LRMR Stock